Autosomal dominant polycystic liver disease results from mutations in PRKCSH or SEC63. The respective gene products, glucosidase II and SEC63p, function in protein translocation and quality control pathways in the endoplasmic reticulum. Here we show that glucosidase II and Sec63p are required in mice for adequate expression of a functional complex of the polycystic kidney disease gene products, polycystin-1 and polycystin-2. We find that polycystin-1 is the rate-limiting component of this complex and that there is a dose-response relationship between cystic dilation and levels of functional polycystin-1 following mutation of Prkcsh or Sec63. Reduced expression of polycystin-1 also serves to sensitize the kidney to cyst formation resulting from mutations in Pkhd1, the recessive polycystic kidney disease gene. Finally, we show that proteasome inhibition increases steady-state levels of polycystin-1 in cells lacking glucosidase II and that treatment with a proteasome inhibitor reduces cystic disease in orthologous gene models of human autosomal dominant polycystic liver disease.
Polycystic liver disease (PLD) is an inherited condition characterized by the presence of multiple scattered cysts of biliary origin throughout the liver parenchyma 1 . PLD occurs frequently as an extra-renal manifestation of autosomal dominant polycystic kidney disease (ADPKD; MIM173900 and MIM173910), but it also exists as a distinct dominantly inherited genetic entity without kidney cysts (ADPLD; MIM174050). Mutations in PRKCSH or SEC63 underlie isolated ADPLD [2] [3] [4] [5] . The SEC63 gene product, SEC63p, works in concert with the SEC61 translocon and BiP to facilitate co-translational translocation across the endoplasmic reticulum (ER) membrane of nascent peptides destined to become either secreted or membrane-inserted proteins [6] [7] [8] . PRKCSH encodes the non-catalytic β-subunit of glucosidase II (GIIβ) 9, 10 . Glucosidase II activity is necessary for proper folding and quality control of proteins passing through the ER translocon 11 . The ADPLD-associated GIIβ subunit contains an ER luminal retention signal and is required for function of the glucosidase II holoenzyme 12 . The two causative genes for ADPKD, PKD1 and PKD2, encode polycystin-1 (PC1) and polycystin-2 (PC2), respectively [13] [14] [15] . PC1 and PC2 are integral membrane proteins thought to function as a Ca 2+ -permeable receptor-channel complex in the cilia membrane [16] [17] [18] . The causative gene for autosomal recessive polycystic kidney disease (ARPKD; MIM263200), PKHD1, encodes fibrocystin/polyductin (FPC), another complex integral membrane protein localized to cilia as well as other cellular compartments [19] [20] [21] .
PC1, PC2 and FPC, along with one Meckel syndrome gene product (MKS3) 22 , are the only integral membrane proteins mutated in cilia-associated fibrocystic diseases 23 . PC1 and FPC are particularly large proteins (>4,000 amino acids) predicted to have extensive post-translational modifications, including proteolytic processing 24, 25 . ADPKD and ADPLD are also unique in that they are the only dominantly inherited traits among the cilia-associated diseases 26 . At the cellular level, kidney and liver cysts in ADPKD occur by a recessive mechanism resulting from somatic second-step mutations [27] [28] [29] . The timing of second hits affects the rate of cyst growth, with perinatal inactivation resulting in more rapid growth; however, adult inactivation of polycystins is sufficient to produce ADPKD 30, 31 . Clinically, liver cysts in ADPLD are indistinguishable from those found in ADPKD 1, 32 , yet GIIβ and SEC63p are the two clearest examples of gene products associated with polycystic disease but not with the cilia-basal-body complex 4 . To understand the mechanisms underlying ADPLD and the role of non-ciliary proteins in polycystic diseases, we used mouse mutants to analyze the genetic and functional interrelationship of Prkcsh and Sec63 with the three major polycystic disease genes encoding membrane-inserted glycoproteins (Pkd1, Pkd2 and Pkhd1). We show that tissue-selective homozygous loss-of-function mutations in Prkcsh or Sec63 result in cyst formation in the kidney as well as in the liver. We further show that loss of either GIIβ or Sec63p results in reduced levels of functional PC1-PC2 complex, with PC1 acting as the rate-limiting A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation Pkd1 dosage determines cyst progression in ADPLD We hypothesized that the basis of cyst formation following inactivation of Prkcsh and Sec63 was related to ADPKD through defective biogenesis and expression of PC1 and PC2. We tested this by reducing the dosage of polycystins using the Pkd1 +/− or Pkd2 +/− backgrounds in the Prkcsh and Sec63 PKD models. The severity of cystic disease as a function of genotype was quantified using kidney weight to body weight ratio, fraction of the total area in kidney sections occupied by cysts (cystic index) and serum urea nitrogen (BUN). Prkcsh flox/flox ; Ksp-Cre and Sec63 flox/flox ; Ksp-Cre mice compounded with either the Pkd1 +/− or Pkd2 +/− background showed increased severity of PKD by all three criteria (Figs. 1c,d  and 2a,b) . The variation between genotypes was significantly greater than the variation within genotypes (Supplementary Figs. 1 and 2) . The structural cystic phenotype with Pkd1 +/− was consistently more severe than with Pkd2 +/− in both Prkcsh and Sec63 models, suggesting a greater sensitivity to the dose of PC1 (Figs. 1c,d and 2a,b and Supplementary Figs. 1 and 2) .
We next used BAC transgenic overexpression of Pkd1 and Pkd2 to evaluate whether dosage of either gene was the predominant determinant of cyst formation in Prkcsh and Sec63 mutant mice on the wild-type background. The Pkd1 F/H -BAC transgenic line (Tg248) has three copies of the transgene and expresses PC1 modified with an NH 2 -terminal triple-FLAG epitope tag and a C-terminal T g 2 4 8 T g 2 7 6 T g 2 7 6 31 , develop liver cysts 8 weeks after treatment with tamoxifen from P28-P32 (black arrows). Expression of the Pkd1 F/H -BAC transgene, but not Pkd2-BAC, abrogates bile duct cyst formation (white arrows). v, venule; c, cyst. Scale bars, 500 µm in the upper panels and 100 µm in the lower panels. (c) The severity of cystic disease is markedly increased on the Pkd1 +/− background and moderately increased on the Pkd2 +/− background. The Pkd1 F/H -BAC transgene rescues the Prkcsh flox/flox ; Ksp-Cre;Pkd2 +/− cystic phenotype; Pkd2-BAC has no effect. Ages, P42; scale bar, 2 mm. triple-hemagglutinin (HA) epitope tag ( Fig. 1e; M. M., Y.C. & S.S., data not shown). Pkd1 F/H -BAC rescues embryonic lethal Pkd1 −/− mice, which remain healthy without kidney cysts for at least 12 months. The Pkd2-BAC line expresses unmodified PC2 at about fourfold higher levels than non-transgenic controls (Fig. 1e) 36 (Fig. 1c,d and data not shown). Pkd1 F/H -BAC had no effect on cysts following complete loss of Pkd2, indicating that PC1 requires some functional PC2 to rescue PKD (Fig. 1f) . In contrast to results in zebrafish models 37 , the Pkd2-BAC transgene had no apparent effect on kidney cysts in Prkcsh flox/flox ; Ksp-Cre; Pkd1 +/− (Fig. 1c,d) or Prkcsh flox/flox ; Ksp-Cre mice. The finding that PC2 is required for PC1 function independently of PC1 dosage is consistent with the existence of an active PC1-PC2 complex 38, 39 .
As ADPLD manifests with liver cysts in humans, we determined whether Pkd1 gene dosage was also the central determinant in bile duct cyst formation. We examined Prkcsh flox/flox ; pCX-Cre mice with and without the Pkd1 F/H -BAC and Pkd2-BAC transgenes eight weeks after tamoxifen induction. We used only male mice to avoid confounding effects of sex in the progression of ADPLD. Pkd1, but not Pkd2, overexpression completely abrogated the ADPLD liver cystic phenotype (Fig. 1b) . We next determined whether the dependence on Pkd1 dosage in ADPLD was applicable to the more severe phenotypes resulting from inactivation of Sec63. The Pkd1 F/H -BAC rescued the cystic phenotype in Sec63 flox/flox ; Ksp-Cre mice, whereas the Pkd2-BAC did not (Fig. 2a,b) . We further examined the interrelationship of Prkcsh and Sec63 using doubly mutant Prkcsh flox/flox ; Sec63 flox/flox ; Ksp-Cre mice (Fig. 2c) . The severity of cyst formation was markedly increased by simultaneous inactivation of both ADPLD genes. Because the products of both genes act in a common biogenetic pathway and because the cystic phenotypes are determined by Pkd1 dosage in both forms of the disease, this additive effect supports the hypothesis that severity of cyst formation in ADPLD is dynamically determined by PC1 levels. to determine the impact on cyst proliferation of two copies of Pkd1 (m,o) compared to a single copy (n,p). We determined the comparative proliferation rates by counting >1,000 DBApositive cystic collecting duct cells per kidney from six kidneys for each genotype. BrdU-positive nuclei are shown in red, DBA is green and DAPI is blue. Scale bar, 20 µm. For both ADPLD models, the increased growth of collecting duct cysts with reduced PC1 dosage on the Pkd1 +/− background was associated with increased proliferation (u) (***P < 0.001; mean ± s.e.m.; Student's t-test).
Prkcsh; Pkd1
(q-t) Representative images comparing apoptotic rates by TUNEL staining (red) for both ADPLD models as a function of Pkd1 dosage. (u) Apoptotic rates measured as above showed more modest increases on the Pkd1 +/− background (u) (**P < 0.01; mean ± s.e.m.; Student's t-test), suggesting that the proliferative effects predominate. DBA, green; scale bar, 20 µm. A r t i c l e s transgene is cleaved into an N-terminal fragment and a C-terminal fragment (CTF), with little residual full-length PC1 remaining in vivo (Fig. 1e) 40 . This allowed us to use the HA-epitope-tagged CTF to monitor PC1 expression (Fig. 3) . Prkcsh −/− cells showed a twofold decrease in steady state levels of PC1 (Fig. 3a) . Kidney tissue from Prkcsh flox/flox ; Ksp-Cre; Pkd1 F/H -BAC mice also showed markedly decreased expression of PC1, thereby extending the cell-based findings to tissue in vivo (Supplementary Fig. 3a) . Sec63-null cells showed similar decreases in PC1 expression (Supplementary Fig. 3b) . Prkcsh −/− cells and Prkcsh flox/flox ; Ksp-Cre cystic kidney tissues had moderately decreased levels of PC2 expression (Fig. 3b) ; Sec63 null cells and tissues also showed similarly decreased PC2 expression ( Supplementary  Fig. 3d ). GIIβ and Sec63p function in generalized protein biosynthetic pathways, and expression of other integral membrane proteins was also affected by the loss of either gene product. For example, NaKATPase was reduced in null cells and cystic kidneys from Prkcsh and Sec63 mutants; the ER resident integral membrane protein calnexin was unchanged (Supplementary Fig. 3c,d) .
The quantitative decrease in PC1 expression in Prkcsh −/− ; Pkd1 F/H -BAC null cells (Fig. 3a) is not different from that expected in the Pkd1 +/− heterozygous state and is unlikely to be sufficient to cause cysts 41 . We therefore hypothesized that cyst formation in the setting of defective GIIβ activity results from functional impairment of the residual PC1 protein. To assess such functional defects, we first examined the resistance of PC1 to digestion by endoglycosidase H (Endo H). Resistance to Endo H is an indicator of trafficking to the cell surface. PC1-CTF in Prkcsh-null cells showed substantial reduction in the fraction of proteins resistant to Endo H (Fig. 3c) , indicating that little of the residual PC1 traffics past the middle Golgi in the absence of GIIβ. The primary cilium has been proposed 26 as the main site of action for PC1 and PC2. Because global measures of the cellular expression and glycosylation status of polycystins may not fully reflect the effects on polycystin function in the minute ciliary compartment, we examined the expression of PC1 and PC2 in the cilia of Prkcsh-null cells. Native PC2 expression was not discernibly different in the cilia of Prkcsh flox/flox ; Pkd1 F/H -BAC and Prkcsh −/− ; Pkd1 F/H -BAC cells (Fig. 3d) . PC2 expression was also unchanged in Sec63 −/− cells compared to Sec63 flox/flox cells (Supplementary Fig. 4 ). PC1 expressed from the Pkd1 F/H -BAC transgene was readily detectable in cilia of Prkcsh flox/flox ; Pkd1 F/H -BAC cells using HA antibodies ( Fig. 3e and Supplementary Fig. 5 ). However, cilia of Prkcsh −/− ; Pkd1 F/H -BAC cells showed markedly reduced or absent expression of PC1 when compared to Prkcsh flox/flox ; Pkd1 F/H -BAC cells (Fig. 3e  and Supplementary Fig. 5 ). As the Pkd1 F/H -BAC transgene rescues the cystic phenotype in vivo, it is likely that this markedly reduced expression level is sufficient for the functional rescue we observed and that the occasional apparent absence of PC1 in cilia by immunofluorescence represents the limitation of our detection. The data show that absence of GIIβ substantially impairs trafficking of PC1 to cilia and suggest that, without transgenic overexpression, the amount of PC1 reaching the cilia is not sufficient to avert cyst formation in ADPLD.
Given the markedly reduced amount of PC1 in cilia even in the setting of BAC transgenic overexpression (Fig. 3e) , we examined whether the rescue of the cystic phenotypes by overexpressed PC1 was durable. Prkcsh flox/flox ; Ksp-Cre; Pkd1 F/H -BAC kidneys remained non-cystic at 3 months, whereas the Pkd2-BAC transgene did not slow cyst progression (Fig. 4a,b) . Microscopically discernible tubular dilation and mild cyst formation did appear at 6 months in Prkcsh flox/flox ; Ksp-Cre; Pkd1 F/H -BAC kidneys, suggesting a marked slowing rather than a complete cessation of expansion in luminal diameter (Fig. 4c) A r t i c l e s but earlier emergence of delayed mild cyst formation with Sec63 flox/flox ; Ksp-Cre; Pkd1 F/H -BAC mice at P45 (Fig. 4d) . In aggregate, these combinatorial genetic data indicate that Prkcsh and Sec63 mediate cystic disease by effectively reducing functional PC1 protein dosage. We show that tubule diameter from mild dilation to cyst formation is a continuously modulated trait determined by PC1 function in a dosage-and time-dependent manner, with an absolute requirement for the presence of functional PC2.
The effects of reduced PC1 dosage differ by nephron segment
Ksp-Cre is active in TAL and the collecting duct segments of the nephron 33, 34 . In both Prkcsh and Sec63 cystic kidneys, the collecting duct formed large cysts, whereas TAL tubules were dilated to a lesser extent (Fig. 5) . This greater severity of collecting duct cysts is similar to the observations in Pkd1 flox/flox ; Ksp-Cre and Pkd2 WS25/− mice 29, 34 . However, conclusions regarding segment-specific sensitivity in these models were potentially confounded by segment-specific differences in either Ksp-Cre activity or somatic second hits, respectively. We took advantage of the additive contribution to cyst formation of the Pkd1 +/− background in ADPLD to evaluate segment-specific sensitivity to Pkd1 dosage without these potential confounding factors. Combination of Prkcsh or Sec63 cystic kidney models with Pkd1 +/− resulted in substantial increases in collecting duct cysts without an appreciable change in TAL tubule dilation (Fig. 5e,f,k,l) . This indicates that reduced dosage of PC1 increases the severity of PKD primarily through increased growth of collecting duct cysts. We next examined the relative contributions of PC1 dosage-dependent proliferation and apoptosis to collecting duct cyst growth in Prkcsh flox/flox ; Ksp-Cre and Sec63 flox/flox ; Ksp-Cre kidneys. The Pkd1 +/− background significantly increased both proliferation (Fig. 5m-p,u) and apoptosis (Fig. 5q-t,u) in the collecting duct cysts of the ADPLD models; increased proliferation appears to predominate (Fig. 5u) . These data provide evidence for segment-specific differences in cyst progression in ADPKD 29, 34 and show that reduced dosage of PC1 facilitates cyst growth through enhanced net proliferation in a manner similar to that seen following complete loss 34 .
PC1 dosage modifies the severity of ARPKD Pkhd1 del4/del4 mice develop a liver phenotype typical of ARPKD and have loss of oriented cell division in elongating tubules but do not develop kidney cysts, perhaps because of residual hypomorphic FPC acitivty 20, 42 . FPC is a client protein for Sec63p and GIIβ, so we examined the interaction between Pkhd1 del4 and Sec63 with the premise that inactivation of Sec63 will eliminate any residual activity of the hypomorphic Pkhd1 del4 gene product (Fig. 6) . Sec63 flox/flox ; Ksp-Cre; Pkhd1 del4/del4 mice developed a more severe cystic disease than Sec63 flox/flox ; Ksp-Cre mice (Fig. 6a-c) , but their disease was not as severe as that of Sec63 flox/flox ; Ksp-Cre; Pkd1 +/− mice ( Supplementary  Fig. 6 ). There was no increase in cyst severity in Sec63 flox/flox ; Ksp-Cre; Pkhd1 del4/+ mice (data not shown). Increased cyst formation in Sec63 flox/flox ; Ksp-Cre; Pkhd1 del4/del4 mice was confined to collecting duct cysts in a pattern that recapitulates findings in Sec63 flox/flox ; Ksp-Cre; Pkd1 +/− mice and in human ARPKD (Fig. 6d) . Because there is evidence of genetic interaction between Pkhd1 and Pkd1 (Supplementary Fig. 7a-c) 43 , we overexpressed PC1 in an effort to separate the interaction of Pkhd1 with Pkd1 from interaction with Sec63. The Pkd1 F/H -BAC transgene markedly rescued the cystic phenotype of Sec63 flox/flox ; Ksp-Cre; Pkhd1 del4/del4 mice; the residual microscopic cystic disease was much less severe than that seen in Sec63 flox/flox ; Ksp-Cre alone (Fig. 6a-c) . This minimal residual disease may be the result of a persistently sensitized background resulting from functional hypomorphism of PC1 even after transgenic re-expression (for example, Figs. 3e and 4d ) and is consistent with the observation that even Pkd1 haploinsufficiency is sufficient to elicit phenotypes in the presence of mutations in Pkhd1 that otherwise do not show kidney cysts (Supplementary Fig. 7a,b) 43 . We also found that reduced PC1 dosage in Pkhd1 del4/del4 ; Pkd1 +/− mice worsened the liver phenotype compared to Pkhd1 del4/del4 alone; however, PC1 overexpression in Pkhd1 del4/del4 ; Pkd1 F/H -BAC mice had no beneficial effect on liver disease (Supplementary Fig. 7c) . Finally, reduced dosage of PC2 by the Pkd2 +/− background had no effect on the Pkhd1 del4/del4 phenotype, supporting the role of PC1 as the rate-limiting factor ( Supplementary  Fig. 7d,e) . The most consistent interpretation of these data is that reduced dosage of PC1 sensitizes kidney tubules and bile ducts to expression of phenotypes resulting from alterations in FPC.
Proteasome inhibitor therapy in ADPLD
Mutations in Prkcsh and Sec63 result in impaired protein biogenesis and quality control and lead to formation of misfolded proteins that undergo retro-translocation and degradation using proteasome-mediated mechanisms 44 . Under this formulation, inhibition of the proteasome may increase the unfolded protein burden to toxic levels, leading to increased sensitivity of cyst cells to proteasome inhibitor therapy. In keeping with this hypothesis, we found that Prkcsh −/− ; Pkd1 F/H -BAC cells showed significantly higher rates of apoptosis following treatment with the proteasome inhibitors MG132 and carfilzomib compared to cells with normal expression of GIIβ ( Fig. 7a and Supplementary Fig. 8 ). In addition, MG132 significantly increased steady-state levels of PC1 in Prkcsh −/− ; Pkd1 F/H -BAC cells, presumably by inhibiting degradation of residual PC1 (Fig. 7b) . These findings suggest that proteasome inhibition may slow cyst progression in ADPLD by increasing cyst-lining cell apoptosis and by decreasing PC1-dependent proliferation (Fig. 7) . We treated severely cystic Prkcsh flox/flox ; Ksp-Cre; Pkd1 +/− mice with the irreversible proteasome inhibitor carfilzomib (5 mg/kg) intravenously twice weekly for 3 weeks beginning at P21 (Fig. 7c,e and Supplementary Fig. 9 ). The efficacy of this regimen was evidenced by increased levels of Hif1α in the kidneys of treated mice (Fig. 7c) . Carfilzomib treatment significantly reduced the kidney weight to body weight ratio, the cystic index and BUN when compared to vehicle-treated controls (Fig. 7e) . The rate of apoptosis in cyst-lining cells of Prkcsh flox/flox ; Ksp-Cre;Pkd1 +/− mice was increased with carfilzomib treatment, whereas the rate of proliferation was decreased (Fig. 7g) . We also tested this therapy in less severely affected Prkcsh flox/flox ; Ksp-Cre mice, which have a genotype more akin to the human disease. Prkcsh flox/flox ; Ksp-Cre mice treated with weekly carfilzomib for 6 weeks beginning at P42 showed an even more profound improvement in cyst progression (Fig. 7d,f and Supplementary Fig. 9 ). Neither mouse model showed adverse effects from proteasome inhibition during treatment. In aggregate, these data suggest that inhibition of proteasome function can improve the course of ADPLD in the orthologous animal models.
DISCUSSION
Sec63p and GIIβ are components of the ER translocation, folding and quality control machinery through which 30% of proteins encoded by the human genome pass, yet heterozygous mutations in these genes manifest only with bile duct cysts indistinguishable from the liver phenotype in ADPKD 1 . Although biochemical and cell biological studies may offer clues, a comprehensive understanding of the genetic and functional interrelationships that define this system requires the use of orthologous gene-based in vivo mammalian models.
Our findings using the latter approach place PC1 at the center of three human polycystic diseases. We produced a spectrum of cystic disease severity using combinations of mutant and overexpression alleles to define the functional interrelationships between five genes: Prkcsh, Sec63, Pkd1, Pkd2 and Pkhd1. Cyst formation in all combinations of these genes, except complete loss of Pkd2, can be significantly modulated by altering expression of Pkd1, indicating that PC1 is the rate-limiting component in cyst formation in human ADPLD, ADPKD and ARPKD. Despite their phenotypic similarities and functional dependence on Pkd1, the mechanisms differ among the three diseases in the current study. In contrast to ADPKD, in which disease typically results from complete somatic loss of Pkd1 or Pkd2, the ADPLD gene orthologs Prkcsh and Sec63 cause cysts by profoundly reducing expression and effective trafficking of functionally active PC1. Evidence for a possible gene-dosage effect for polycystins was first described in trans heterozygous states in humans 45 and mice 41 . More recently, mutations in Pkd1 resulting in reduction of functional PC1 have suggested that reduced activity is sufficient to cause cyst formation in some situations [46] [47] [48] . Our data define a more complex relationship. The variables that determine tubule dilation and cyst formation include the level of PC1 expression, the threshold below which progressive tubule dilation can begin, the degree to which PC1 activity falls below this threshold and the activity of other factors that determine the extent of response once tubule dilation and cyst formation is initiated. The quantitative features of these determinants are likely to vary between bile ducts and kidney tubules and between different segments and cell types within kidney tubules. These differences may underlie the liver-specific findings in ADPLD compared to the kidney predominance in ADPKD. We hypothesize that in individuals with ADPLD, somatic loss of either SEC63 or PRKCSH may occur in either kidney tubules or bile ducts. The basis for the clinical difference in ADPLD and ADPKD may be that, in ADPLD, the ensuing decrease in PC1 activity in bile ducts falls to a level sufficient to cause PLD, but the decrease in PC1 activity in kidney tubules is not sufficient to cause PKD.
Our data show another feature of cyst formation. The threshold and rate for cyst growth is not a binary on-off process but rather a continuously regulated process. Reducing PC1 levels with Prkcsh mutation alone results in cyst growth; further reducing the equilibrium of the PC1-PC2 functional complex by combining Prkcsh mutation with the Pkd2 +/− background increases the rate of cyst growth. A more profound increase in cyst growth is seen on the Pkd1 +/− background. These findings suggest that the farther below the threshold PC1-PC2 activity falls, the greater the rate of tubule dilation and cyst growth. The increased cyst formation in Sec63; Prkcsh double knockouts further supports this conclusion. None of these models grow cysts as rapidly as the model with complete inactivation of Pkd1 (ref. 34) , so the continuum of cyst growth rates shows a substantial amount of dynamism. The differences in the rate of cyst growth between the collecting duct and TAL on the Pkd1 +/+ and Pkd1 +/− backgrounds suggest that specific cell types can have different responses to PC1-dependent signal dosage variation.
We found that a Pkhd1 mutation that does not result in a kidney phenotype in mice nonetheless results in worsened kidney cysts when combined with mutation of Sec63. The kidney cysts in the Pkhd1; Sec63 mice were largely rescued by PC1 overexpression, supporting the conclusion that reduced PC1 dosage sensitizes mice with mutations in Pkhd1 to polycystic kidney phenotypes. The Pkhd1 del4 mutation causes loss of oriented cell division without cyst formation 42 . It is possible that, when coupled with a propensity toward proliferation resulting from reduced PC1 dosage, Pkhd1-dependent defects in A r t i c l e s oriented cell division are sufficient to exacerbate cyst growth in mice. The inability of PC1 overexpression to improve the liver phenotype in Pkhd1 del4/del4 mice suggests that Pkhd1 also has PC1-independent functions in bile ducts. It is possible that the functional relationship between PC1 and FPC is conserved between humans and mice. A plausible hypothesis for the observed species differences in the ARPKD kidney phenotype may be that the normal level of PC1 expression in humans is closer to the threshold for eliciting a PKHD1 mutant phenotype than it is in mice.
The finding that proteasome inhibitor therapy is effective in our orthologous model of ADPLD offers a conceptual therapeutic approach to ADPLD. The clinical utility of this approach will need to be tempered by the side effect profile relative to potential benefit, but the heightened sensitivity of cells with mutations in the ADPLD genes to proteasome inhibition may offer an improved therapeutic index in this regard. We observed decreased degradation of improperly processed PC1 following proteasome inhibition. In light of this and the acute sensitivity of cyst formation to PC1 'dose' , investigation of the utility of proteasome inhibition in orthologous models of ADPKD based on hypomorphic and amino acid substitution variants of Pkd1 may be warranted.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
